Avito launched a new cross-linked sodium hyaluronate, welcome to apply!
According to a report by Frost&Sullivan, China has become the world's third largest medical beauty market, with the market size reaching 189.12 billion yuan in 2021 and is expected to reach 399.81 billion yuan in 2026. Among them, light medical beauty projects by virtue of simple operation, quick recovery, low risk, low price advantages, occupy about 60% of the medical beauty market, which is dominated by hyaluronic acid products.
In 2021, the market size of China's medical beauty hyaluronic acid terminal products is still larger than other pharmaceutical grade terminal applications, reaching 6.43 billion yuan, with a compound growth rate of 19.7% from 2017 to 2021, and is expected to reach 19.62 billion yuan with a compound growth rate of 25.0% in 2026.
Hyaluronic acid medical beauty products mainly include two categories: water needle and HA filler. Water needle is generally not cross-linked or micro-cross-linked HA as the main component, focusing on hydration and moisturizing; The active component of HA filler is HA after crosslinking, which has stronger mechanical properties, better shaping effect after treatment and longer maintenance time.
The main component of HA filler is crosslinked sodium hyaluronate gel, and the removal of crosslinking process and residual crosslinking agent is the key technical difficulty of this kind of product, and it is also the bottleneck problem faced by medical and beauty manufacturers.
At present, the sodium hyaluronate crosslinking agents that can be seen on the market are 1, 4-butanediol diepoxide glycerol ether (BDDE) and diethyl Xiyl sulfone (DVS). The crosslinked sodium hyaluronate gels prepared by the two crosslinking agents have different physical properties: DVS crosslinking activity is high, and the crosslinked sodium hyaluronate gels are hard; BDDE crosslinked products have soft texture, mild reaction and large expansion rate, and more than 80% of sodium hyaluronate injection products on the market currently use BDDE.
Industry standard YY/T 0962-2021 regulates the specific parameters of crosslinked sodium hyaluronate gel for plastic surgery, among which the residue of crosslinking agent BDDE is required to be controlled below 2μg/g (see the following figure), and the limit requirements and detection methods are required for other crosslinking agents. At present, the control of products in the industry for BDDE can generally reach below 0.5μg/g, the lower the better.
AVT crosslinked sodium hyaluronate gel is made of pharmaceutical injection grade sodium hyaluronate produced by Keube Co., LTD., Japan, as the raw material, adhering to the pharmaceutical standard escort injection medical beauty. Kewpy injection grade sodium hyaluronate has been registered in CDE, and 2 of them have completed drug association review and turned into A state. Compared with similar products, Chewbee HA has four advantages: lower internal toxin ...
(All Rights Reserved)